We appreciate the comments of Pesola and colleagues regarding our study of airway hyperreactivity (AHR) in patients with sarcoidosis.1In order to determine if endobronchial biopsy (EBB) should be performed during bronchoscopy for suspected sarcoidosis, they suggest that clinicians rely on the results of formal AHR testing. If AHR is present, they imply, then EBB would be useful. However, if AHR is absent, then EBB should be avoided. We disagree. First, the yield of EBB is high, irrespective of the presence or absence of AHR. As we showed in an earlier analysis2 of a diverse cohort of patients, EBB findings are positive in > 60% of subjects. More importantly, the addition of EBB to transbronchial biopsy increases the diagnostic yield of bronchoscopy by 20%. Second, EBB is safe and minimally increases the length of the procedure. This point is particularly important, since a more invasive and costly intervention such as mediastinoscopy might be required if a bronchoscopy is nondiagnostic. In short, the risk-benefit ratio associated with EBB favors employing this technique routinely in cases of suspected sarcoidosis.